In a treatment-naïve ovarian tumor-bearing mouse model, upfront combination therapy effectively promoted an anti-tumor microenvironment, as evidenced by an increase in CD86+CD206- macrophage cells and a concomitant decrease in CD86-CD206+ macrophage cells. This evidence concerns the gene CD86 and ovarian neoplasm.